Welcome to our dedicated page for MCKESSON SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MCKESSON's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MCKESSON's regulatory disclosures and financial reporting.
McKesson Corporation (MCK) has filed a DEFA14A with the U.S. Securities and Exchange Commission, indicating the submission of definitive additional proxy soliciting materials. The filing is made by the registrant itself, and the company has marked the box showing that no filing fee is required. No preliminary proxy, confidential treatment, or soliciting material under Rule 14a-12 boxes were selected. Beyond these administrative details, the document contains no financial data, transactional information, or new proposals.
McKesson Corporation (MCK) has filed its Definitive Proxy Statement (DEF 14A) ahead of the June 20, 2025 Annual Meeting. The document emphasises the Board’s oversight of culture, strategy and long-term value creation under the company’s purpose, “Advancing Health Outcomes for All®.” Independent Chair Donald R. Knauss thanks shareholders for their ongoing support and outlines how the Board has monitored execution against four stated priorities: 1) focus on people and culture, 2) strengthen North-American pharmaceutical distribution, 3) modernise and accelerate the portfolio, and 4) enhance oncology and biopharma services platforms.
Operational progress in FY 2025:
- Share-price performance: disciplined execution across the business contributed to a 25 % increase in McKesson’s stock price during FY 2025.
- Portfolio optimisation: in December, McKesson divested its Canada-based Rexall and Well.ca businesses, freeing capital for oncology and biopharma services investments.
- Customer momentum: the company onboarded several new customers and expanded a key pharmaceutical distribution relationship, reinforcing its sourcing and distribution capabilities.
- Digital enablement: a company-wide training programme is promoting a digital-first mindset, including the use of artificial intelligence, to drive efficiency and value creation.
- Regulatory posture: the Board states it continues to oversee McKesson’s commitment to “regulatory excellence and compliance with applicable laws.”
Human-capital highlights: Management stresses its I²CARE values (Integrity, Inclusion, Customer-First, Accountability, Respect, Excellence) and ILEAD leadership framework as cultural cornerstones designed to unite its global workforce and sustain performance.
The proxy statement is marked “Definitive,” no filing fee is required, and no preliminary or additional solicitation materials accompany the submission. Financial tables referenced in the XBRL block appear to relate mainly to executive compensation and equity-award valuation; specific dollar amounts, cash-flow figures or earnings data are not included in the excerpt.
For investors, the filing provides qualitative confirmation that McKesson is aligning capital deployment and talent development with its stated strategy, while the 25 % share-price appreciation and Canada divestiture represent tangible outcomes of that strategy.